Published in Medical Letter on the CDC and FDA, January 7th, 2007
"The business development activity conducted over the past eighteen months, including the U.S. Food & Drug Administration clearance for HemoNIR, continues to pay dividends as awareness grows among potential partners of the multiple applications for our light-based technology," said Duncan MacIntyre, president, CEO and executive vice chairman of NIR Diagnostics.
Our chief priority in the coming...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.